CAS
SRNE

Coppell Advisory Solutions’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Coppell Advisory Solutions’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$89 – 1928
2023
Q3 		$89 Buy
+100
New +$89 ﹤0.01% 1148
2023
Q1 		– Sell
-100
Closed -$89 – 1202
2022
Q4 		$89 Buy
+100
New +$133 ﹤0.01% 1150

Other funds holding SRNE

LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
KA
KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return
SW
SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return
HCM
Highlander Capital Management Short Hills, New Jersey $292M AUM 22.24% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.68B AUM

Coppell Advisory Solutions's SRNE Position: Q4 2023 in Review

Coppell Advisory Solutions sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2023, closing a stake of 100 shares — an estimated $89 sold.

Coppell Advisory Solutions first reported a position in SRNE in Q4 2022 and held it in 2 quarters. The position peaked at $89 in Q3 2023. 9 funds tracked by Wall St. Rank hold SRNE as of Q4 2023.

  • Coppell Advisory Solutions reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
  • Coppell Advisory Solutions sold 100 Sorrento Therapeutics, Inc. shares in Q4 2023, an estimated $89.
  • Coppell Advisory Solutions first reported a position in Sorrento Therapeutics, Inc. in Q4 2022 and held it in 2 quarters.
  • Coppell Advisory Solutions's Sorrento Therapeutics, Inc. position peaked at $89 in Q3 2023.
  • 9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2023.

Based on Coppell Advisory Solutions's 13F filing for Q4 2023, filed 14 Feb 2024.